Results 101 to 110 of about 272,115 (210)
PLoS ONE, 2022 Administration of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line therapy for diabetic macular oedema (DME). However, some patients show no or insufficient response to repeated anti-VEGF injections.
Makoto Hatano +8 more
doaj
Inflammatory and angiogenic protein detection in the human vitreous : cytometric bead assay [PDF]
, 2011 Introduction. To evaluate clinical feasibility and reproducibility of cytometric bead assay (CBA) in nondiluted vitreous samples of patients with age-related macular degeneration (ARMD), diabetic macular edema (DME), and central retinal vein occlusion ...
Koch, Frank H. +2 more
core
Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice
Scientific ReportsMedication-related osteonecrosis of the jaw (MRONJ) is a detrimental side effect in patients undergoing treatment with antiresorptive agents. The anti-angiogenic agent, bevacizumab (anti-VEGF antibody (Ab)), has also been reported to be associated with ...
Eun-Bin Bae +11 more
doaj +1 more source
Tumor refractoriness to anti-VEGF therapy
Oncotarget, 2016 Vascular endothelial growth factor (VEGF) has been identified as the most potent cytokine involved in tumor angiogenesis and metastasis formation. Clinical results of anti-angiogenic therapies targeting VEGF and its receptors are very modest, resulting in a moderate improvement of overall survival.
openaire +4 more sources
An overview on Anti-Vegf and in search for an ideal anti VEGF agent
Indian Journal of Clinical and Experimental Ophthalmology, 2022 openaire +1 more source
Indian Journal of OphthalmologyThe emergence of anti-vascular endothelial growth factor (anti-VEGF) therapy has marked a paradigm shift in the treatment of retinal and choroidal vascular diseases.
Chitaranjan Mishra +4 more
doaj +1 more source
Brolucizumab—another anti-VEGF or beyond [PDF]
Eye, 2020 Sharma, Ashish +6 more
openaire +4 more sources
Anti-VEGF drugs in the prevention of blindness.
Community eye health, 2014 Disorders of the blood vessels in the retina are responsible for some of the most common causes of blindness in the world.
openaire +2 more sources
Anti – VEGF in Treatment of Diabetic Macular Edema
Collegium antropologicum, 2012 Diabetic macular edema is the leading cause of moderate visual deterioration in patients with diabetic retinopathy. Ranibizumab) blocks vascular endothelial growth factor (VEGF) induced hyperpermeability of blood vessels. In this prospective case series we investigated the efficacy and safety of anti-VEGF treatment in reduction of central retinal ...
Boras, Ivan +4 more
openaire +3 more sources